Alfuzosin
Instructions for use:
- 1. Release form and composition
- 2. Indications for use
- 3. Contraindications
- 4. Method of application and dosage
- 5. Side effects
- 6. Special instructions
- 7. Drug interactions
- 8. Analogs
- 9. Terms and conditions of storage
- 10. Terms of dispensing from pharmacies
Alfuzosin is a selective blocker of alpha 1 -adrenergic receptors (mainly in the area of the urethra, prostate and bladder triangle), which reduces pressure in the urethra, reduces resistance to urine flow, facilitates urination and eliminates dysuria.
Release form and composition
- Prolonged-release tablets: round, flat-cylindrical, white or white with a yellowish tinge, with a chamfer (10 pcs. In blisters, in a cardboard box 1, 3, 5 or 6 packages; 14 pcs. In blisters, in a carton box 1, 2 or 4 packages);
- Film-coated controlled release tablets: round, biconvex, light yellow with a faint brownish tinge; at the break - white or almost white (10 pcs. in blisters, 6 packs in a cardboard box).
The active substance is alfuzosin hydrochloride:
- 1 prolonged-release tablet - 5 or 10 mg;
- 1 controlled release tablet - 5 mg.
Auxiliary components of prolonged-release tablets: Kollidon SR (polyvinyl acetate, povidone, sodium lauryl sulfate, silicon dioxide), magnesium stearate, lactose monohydrate, colloidal silicon dioxide.
Additional substances of controlled release tablets: magnesium stearate for the pharmaceutical industry, medium molecular weight povidone (medium molecular weight polyvinylpyrrolidone), hyprolose (hydroxypropyl cellulose), calcium hydrogen phosphate dihydrate (calcium phosphate disubstituted 2-water), microcrystalline cellulose, hypo-methylcellulose, titanium dioxide (titanium dioxide) hydrogenated castor oil, iron oxide yellow dye.
Indications for use
Alfuzosin is a drug for the treatment of functional disorders of urination caused by benign prostatic hyperplasia.
Contraindications
- Severe liver failure;
- Orthostatic hypotension (including a history);
- Simultaneous use of other alpha-blockers;
- Hypersensitivity to drug components.
Alfuzosin is not used to treat women.
Carefully:
- Chronic renal failure
- Cardiac ischemia;
- Age over 75;
- Simultaneous use of antihypertensive drugs.
Method of administration and dosage
Alfuzosin should be taken orally by swallowing the tablets whole and drinking plenty of water.
The recommended daily dose is 10 mg - 1 tablet 10 mg once a day or 1 tablet 5 mg 2 times a day, in the morning and in the evening, while treatment should be started with an evening dose.
Elderly people and patients who receive concomitant antihypertensive therapy are prescribed 5 mg 1 time per day (in the evening). If necessary, it is possible to increase the dose to 10 mg.
Side effects
- From the digestive system: nausea, dry mouth, diarrhea, epigastric pain;
- On the part of the cardiovascular system: orthostatic hypotension, tachycardia; in patients with ischemic heart disease - exacerbation of symptoms of angina pectoris;
- From the nervous system: dizziness, headache, drowsiness, weakness, asthenic syndrome;
- Allergic reactions: itching, skin rashes;
- Others: skin hyperemia, tinnitus, edema.
special instructions
In some cases, especially in patients receiving antihypertensive drugs, postural hypotension may develop within a few hours after taking Alfuzosin, with or without symptoms (sweating, fatigue and dizziness). Such persons need to remain in the supine position until the condition improves. These phenomena are often temporary, occur at the beginning of therapy and, as a rule, are not a reason for discontinuation of the drug.
With the combined use of antihypertensive drugs, especially calcium channel blockers, it is necessary to adjust their doses, because a decrease in blood pressure is possible, up to the development of a collapse.
Patients with coronary insufficiency should take Alfuzosin simultaneously with specific treatment for coronary insufficiency. If angina pectoris returns or worsens, Alfuzosin should be canceled.
There are no data on the negative effect of the drug on the speed of reactions and the ability to concentrate. However, at the beginning of treatment, asthenia and dizziness may occur, so patients should be careful when driving and performing potentially dangerous types of work.
Drug interactions
Alfuzosin should not be used concomitantly with other alpha 1 -adrenergic blockers, since the hypotensive effect is enhanced, as a result of which the risk of severe postural hypotension increases.
The drug enhances the effect of antihypertensive drugs, including blockers of slow calcium channels (an additive effect is noted) and general anesthetics (instability of blood pressure is possible).
With the simultaneous use of inhibitors of the CYP3A4 system (itraconazole, ketoconazole, ritonavir), the concentration of alfuzosin in the blood increases.
Analogs
Alfuzosin analogs are: Alfuprost MR, Dalfaz, Dalfaz SR, Dalfaz Retard.
Terms and conditions of storage
Store at temperatures up to 25 ºС out of reach of children, protected from light and in a dry place.
Shelf life is 2 years.
Terms of dispensing from pharmacies
Dispensed by prescription.
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!
